These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33573707)

  • 1. Feedback-Based Learning of Timing in Attention-Deficit/Hyperactivity Disorder and Neurofibromatosis Type 1.
    Prochnow A; Bluschke A; Novotna B; von der Hagen M; Beste C
    J Int Neuropsychol Soc; 2022 Jan; 28(1):12-21. PubMed ID: 33573707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Motor dysfunction in NF1: Mediated by attention deficit or inherent to the disorder?
    Haas-Lude K; Heimgärtner M; Winter S; Mautner VF; Krägeloh-Mann I; Lidzba K
    Eur J Paediatr Neurol; 2018 Jan; 22(1):164-169. PubMed ID: 29111114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attention and Executive Disorders in Neurofibromatosis 1: Comparison Between NF1 With ADHD Symptomatology (NF1 + ADHD) and ADHD Per Se.
    Lion-François L; Herbillon V; Peyric E; Mercier C; Gérard D; Ginhoux T; Coutinho V; Kemlin I; Kassai B; Desportes V; Michael GA
    J Atten Disord; 2020 Nov; 24(13):1807-1823. PubMed ID: 28587546
    [No Abstract]   [Full Text] [Related]  

  • 4. Guanfacine treatment improves ADHD phenotypes of impulsivity and hyperactivity in a neurofibromatosis type 1 mouse model.
    Lukkes JL; Drozd HP; Fitz SD; Molosh AI; Clapp DW; Shekhar A
    J Neurodev Disord; 2020 Jan; 12(1):2. PubMed ID: 31941438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of ADHD in neurofibromatosis type 1.
    Mautner VF; Kluwe L; Thakker SD; Leark RA
    Dev Med Child Neurol; 2002 Mar; 44(3):164-70. PubMed ID: 12005317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attention and Motor Learning in Adult Patients with Neurofibromatosis Type 1.
    Castricum J; Tulen JHM; Taal W; Rietman AB; Elgersma Y
    J Atten Disord; 2022 Feb; 26(4):563-572. PubMed ID: 33978520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Executive dysfunction in children with neurofibromatosis type 1: a study of action planning.
    Roy A; Roulin JL; Charbonnier V; Allain P; Fasotti L; Barbarot S; Stalder JF; Terrien A; Le Gall D
    J Int Neuropsychol Soc; 2010 Nov; 16(6):1056-63. PubMed ID: 20682087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of ADHD on the cognitive and academic functioning of children with NF1.
    Pride NA; Payne JM; North KN
    Dev Neuropsychol; 2012; 37(7):590-600. PubMed ID: 23066937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paired associate learning in children with neurofibromatosis type 1: implications for clinical trials.
    Payne JM; Barton B; Shores EA; North KN
    J Neurol; 2013 Jan; 260(1):214-20. PubMed ID: 22875098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autism and attention-deficit/hyperactivity disorders and symptoms in children with neurofibromatosis type 1.
    Morotti H; Mastel S; Keller K; Barnard RA; Hall T; O'Roak BJ; Fombonne E
    Dev Med Child Neurol; 2021 Feb; 63(2):226-232. PubMed ID: 32406525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using a Virtual Classroom environment to describe the attention deficits profile of children with Neurofibromatosis type 1.
    Gilboa Y; Rosenblum S; Fattal-Valevski A; Toledano-Alhadef H; Rizzo AS; Josman N
    Res Dev Disabil; 2011; 32(6):2608-13. PubMed ID: 21757320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does attention-deficit-hyperactivity disorder exacerbate executive dysfunction in children with neurofibromatosis type 1?
    Payne JM; Arnold SS; Pride NA; North KN
    Dev Med Child Neurol; 2012 Oct; 54(10):898-904. PubMed ID: 22845611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1.
    Payne JM; Haebich KM; MacKenzie R; Walsh KS; Hearps SJC; Coghill D; Barton B; Pride NA; Ullrich NJ; Tonsgard JH; Viskochil D; Schorry EK; Klesse L; Fisher MJ; Gutmann DH; Rosser T; Packer RJ; Korf B; Acosta MT; Bellgrove MA; North KN
    J Atten Disord; 2021 Jun; 25(8):1177-1186. PubMed ID: 31838937
    [No Abstract]   [Full Text] [Related]  

  • 14. An executive functioning perspective in neurofibromatosis type 1: from ADHD and autism spectrum disorder to research domains.
    Smith TF; Kaczorowski JA; Acosta MT
    Childs Nerv Syst; 2020 Oct; 36(10):2321-2332. PubMed ID: 32617712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TAND checklist: a useful screening tool in children with tuberous sclerosis and neurofibromatosis type 1.
    Cervi F; Saletti V; Turner K; Peron A; Bulgheroni S; Taddei M; La Briola F; Canevini MP; Vignoli A
    Orphanet J Rare Dis; 2020 Sep; 15(1):237. PubMed ID: 32894194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trial.
    Pride NA; Barton B; Hutchins P; Coghill DR; Korgaonkar MS; Hearps SJC; Rouel M; Malarbi S; North KN; Payne JM
    BMJ Open; 2018 Aug; 8(8):e021800. PubMed ID: 30166301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feedback-based probabilistic category learning is selectively impaired in attention/hyperactivity deficit disorder.
    Gabay Y; Goldfarb L
    Neurobiol Learn Mem; 2017 Jul; 142(Pt B):200-208. PubMed ID: 28478078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of phenylketonuria with attention deficit hyperactivity disorder: do markedly different aetiologies deliver common phenotypes?
    Stevenson M; McNaughton N
    Brain Res Bull; 2013 Oct; 99():63-83. PubMed ID: 24140048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurofibromatosis type 1 and attention deficit hyperactivity disorder: a case study and literature review.
    Miguel CS; Chaim-Avancini TM; Silva MA; Louzã MR
    Neuropsychiatr Dis Treat; 2015; 11():815-21. PubMed ID: 25848279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A preliminary study of the different memory systems in neurofibromatosis type 1: What is impaired and what is spared?
    Maziero S; Jucla M; Blais M; Albaret JM; Tallet J; Chaix Y
    Brain Dev; 2023 Apr; 45(4):220-230. PubMed ID: 36609051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.